Khaled Ezzedine1, Maggi Ahmed2, Andrea Tovar-Garza3, Carla Hajj4, Maxine Whitton5, Amit Pandya3, Saad Altalhab6, Julien Seneschal7, John Harris2, Charles Taieb8. 1. Department of Dermatology, Mondor Hospital (AP-HP), Paris Est Créteil University, Créteil, France; Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE), EA7379, Paris-Est University, Créteil, France. Electronic address: khaled.ezzedine@aphp.fr. 2. Department of Dermatology, University of Massachusetts Medical School, Worcester, Massachusetts. 3. University of Texas Southwestern Medical Center, Dallas, Texas. 4. Department of Dermatology, Mondor Hospital (AP-HP), Paris Est Créteil University, Créteil, France. 5. Cochrane Skin Group, Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK. 6. Department of Dermatology, College of Medicine, Al Imam Mohammad Ibn Saud Islamic University, Riyadh, Saudi Arabia. 7. Hôpital Saint-André, CHU Bordeaux, Bordeax, France. 8. FIMARAD, Hôpital Necker-Enfants Malades, Paris, France.
Abstract
BACKGROUND: There is a lack of short-form questionnaires evaluating the burden of vitiligo according to skin phototype. OBJECTIVE: To develop and validate a 12-item short-form of the Vitiligo Impact Patient scale (VIPs) that takes into account skin phototype. METHODS: Multicenter, prospective, cross-sectional study conducted in France (Créteil and Bordeaux) and the US (Worcester, Massachusetts, and Dallas, Texas). RESULTS: In total, 891 patients completed the questionnaire. Of these, 509 patients belonged to the French Development sample-313 with dark skin (DS) (phototypes IV to VI) and 196 with fair skin (FS) (phototypes I to III). The US validation sample comprised 382 patients-113 DS and 269 FS. There was a very high correlation between VIPs-FS and its 12-item short-form, VIPs-12-FS, in both the development and validation samples (respectively, rho = 0.96, P < .0001 and rho = 0.98, P < .0001). Similarly, the correlations between VIPs-DS and its short-form, VIPs-12-DS, in both the development and validation samples were very high (respectively, rho = 0.95, P < .0001 and rho = 0.96, P < .0001). LIMITATIONS: Responsiveness of the 12-item short-forms should be confirmed. CONCLUSIONS: These data enabled the development and validation of 12-item short-forms of the VIPs questionnaires for fair (VIPs-12-FS) and dark (VIPs-12-DS) skin.
BACKGROUND: There is a lack of short-form questionnaires evaluating the burden of vitiligo according to skin phototype. OBJECTIVE: To develop and validate a 12-item short-form of the Vitiligo Impact Patient scale (VIPs) that takes into account skin phototype. METHODS: Multicenter, prospective, cross-sectional study conducted in France (Créteil and Bordeaux) and the US (Worcester, Massachusetts, and Dallas, Texas). RESULTS: In total, 891 patients completed the questionnaire. Of these, 509 patients belonged to the French Development sample-313 with dark skin (DS) (phototypes IV to VI) and 196 with fair skin (FS) (phototypes I to III). The US validation sample comprised 382 patients-113 DS and 269 FS. There was a very high correlation between VIPs-FS and its 12-item short-form, VIPs-12-FS, in both the development and validation samples (respectively, rho = 0.96, P < .0001 and rho = 0.98, P < .0001). Similarly, the correlations between VIPs-DS and its short-form, VIPs-12-DS, in both the development and validation samples were very high (respectively, rho = 0.95, P < .0001 and rho = 0.96, P < .0001). LIMITATIONS: Responsiveness of the 12-item short-forms should be confirmed. CONCLUSIONS: These data enabled the development and validation of 12-item short-forms of the VIPs questionnaires for fair (VIPs-12-FS) and dark (VIPs-12-DS) skin.
Authors: Yuan-Ting Yang; Chung-Hao Hsu; Yu-Fen Wang; Yu-Jun Chang; Hui-Ju Yang; Jiunn-Liang Ko; Kuo-Chia Yang Journal: Int J Environ Res Public Health Date: 2022-05-31 Impact factor: 4.614
Authors: Khaled Ezzedine; Viktoria Eleftheriadou; Heather Jones; Kristen Bibeau; Fiona I Kuo; Daniel Sturm; Amit G Pandya Journal: Am J Clin Dermatol Date: 2021-09-23 Impact factor: 7.403
Authors: N van Geel; S E Uitentuis; M Zuidgeest; A Wolkerstorfer; M W Bekkenk; C Moock; C Van Goethem; E Verlaeckt; C Smet; L Grine; R Speeckaert Journal: J Eur Acad Dermatol Venereol Date: 2020-09-01 Impact factor: 9.228
Authors: V S Narayan; S E Uitentuis; R M Luiten; M W Bekkenk; A Wolkerstorfer Journal: J Eur Acad Dermatol Venereol Date: 2020-10-07 Impact factor: 6.166